Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
49
DXR Quote, Financials, Valuation and Earnings
Last price:
$12.50
Seasonality move
:
3.18%
Day range:
$12.40 - $12.90
52-week range:
$7.00 - $14.76
Dividend yield:
0%
P/E ratio:
40.36x
P/S ratio:
57.50x
P/B ratio:
1.70x
Volume:
1.1K
Avg. volume:
6.8K
1-year change:
73.91%
Market cap:
$72.3M
Revenue:
-$135.7K
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingDaxor Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.50, Daxor Corp. has an estimated upside of 81.45% from its current price of $12.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $22.00 representing -77.42% downside risk from its current price of $12.40.
Fair Value
-
According to the consensus of 1 analyst, Daxor Corp. has 81.45% upside to fair value with a price target of $22.50 per share.
DXR vs. S&P 500
-
Over the past 5 trading days, Daxor Corp. has overperformed the S&P 500 by 1.91% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Daxor Corp. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Daxor Corp. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Daxor Corp. reported revenues of --.
Earnings Growth
-
Daxor Corp. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Daxor Corp. reported earnings per share of --.
Enterprise value:
5.9M
EV / Invested capital:
--
Price / LTM sales:
57.50x
EV / EBIT:
3.20x
EV / Revenue:
5.54x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
3.20x
Gross Profit (TTM):
$914K
Return On Assets:
1.52%
Net Income Margin (TTM):
25.17%
Return On Equity:
1.57%
Return On Invested Capital:
1.52%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2009-12-31 | 2010-12-31 | 2011-12-31 | 2010-12-31 | 2011-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $361.4K | $369.8K | |
| Gross Profit | -- | -- | -- | $176.7K | $192.9K | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | $0.53 | -$0.35 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $20.8K | $26.1K | $10.9K | $13.7K | -- | |
| Total Assets | $16.7M | $22.4M | $30.4M | $34.4M | -- | |
| Current Liabilities | -- | $16.5K | -- | -- | -- | |
| Total Liabilities | $2.2M | $2.8M | -- | $1.7M | -- | |
| Total Equity | $14.5M | $19.6M | $30.4M | $32.7M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2009-12-31 | 2010-12-31 | 2011-12-31 | 2010-12-31 | 2011-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$1.8M | -$989.9K | |
| Cash From Investing | -- | -- | -- | $6.5M | -$8.1M | |
| Cash From Financing | -- | -- | -- | -$4.7M | $9.1M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
DXR
Sector
Market Cap
$72.3M
$24M
Price % of 52-Week High
84.02%
48.29%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.62%
1-Year Price Total Return
73.91%
-22.92%
Beta (5-Year)
0.011
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$12.37
200-day SMA
Buy
Level
$11.30
Bollinger Bands (100)
Sell
Level
12.39 - 13.73
Chaikin Money Flow
Sell
Level
-6.4M
20-day SMA
Sell
Level
$12.69
Relative Strength Index (RSI14)
Sell
Level
44.92
ADX Line
Buy
Level
11.57
Williams %R
Buy
Level
-83.3333
50-day SMA
Sell
Level
$13.09
MACD (12, 26)
Sell
Level
-0.28
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
40.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (27.1422)
Buy
CA Score
(Annual)
Level (1.7975)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.4554)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage and andrology services, such as semen analysis, sperm washing, and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in Oak Ridge, TN.
Stock Forecast FAQ
In the current month, DXR has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DXR average analyst price target in the past 3 months is $22.50.
-
Where Will Daxor Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Daxor Corp. share price will rise to $22.50 per share over the next 12 months.
-
What Do Analysts Say About Daxor Corp.?
Analysts are divided on their view about Daxor Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Daxor Corp. is a Sell and believe this share price will drop from its current level to $22.00.
-
What Is Daxor Corp.'s Price Target?
The price target for Daxor Corp. over the next 1-year time period is forecast to be $22.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DXR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Daxor Corp. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of DXR?
You can purchase shares of Daxor Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Daxor Corp. shares.
-
What Is The Daxor Corp. Share Price Today?
Daxor Corp. was last trading at $12.50 per share. This represents the most recent stock quote for Daxor Corp.. Yesterday, Daxor Corp. closed at $12.40 per share.
-
How To Buy Daxor Corp. Stock Online?
In order to purchase Daxor Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DXR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DXR
Sector
P/E ratio
40.36x
23.44x
PEG ratio
--
-0.01x
P/B ratio
1.70x
1.73x
Price / LTM sales
57.50x
1.51x
Growth Metrics
DXR
Sector
Revenue growth
--
3.31%
Earnings growth
--
10.7%
Revenue (5-year growth)
--
6.28%
Earnings forecast
--
-$0.19
Profitability
DXR
Sector
Profitability FY 2024
-$300.6K
$2.6M
Return on invested capital
1.52%
-33.62%
Return on assets
1.52%
-29.74%
Return on equity
1.57%
-39.33%
Earnings Date
Last Earnings Date
Aug
29
Next Earnings Date
Feb
15
Estimated Next Earnings Date
May
17
Balance Sheet
DXR
Sector
Total cash
--
$25M
Short term investments
--
$23.9M
Total assets
$36.6M
$71.9M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
